TY - JOUR
T1 - Determination of the metabolic profile of gentianine after oral administration to rats by high performance liquid chromatography/electrospray ionization-trap mass spectrometry
AU - Wu, Xiuhong
AU - Tang, Shuhan
AU - Jin, Yan
AU - Wang, Shanshan
AU - Wang, Xijun
AU - Hattori, Masao
AU - Zhang, Hailong
AU - Wang, Zhigang
N1 - Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - We investigated the metabolic fate of gentianine after oral administration to Wistar rats for the first time. Liquid chromatography/ion trap mass spectrometry detected four metabolites secogentianoxide, gentiandiol, gentianepoxide and gentianoxide in rat plasma together with the original compound gentianine. The structures of the metabolites were identified by comparing the retention times, as well as MS (mass) and MS/MS (tandem mass) spectra with those of authentic compounds, which were synthesized from gentianine or isolated from the urine. Three of the metabolites, secogentianoxide, gentianepoxide and gentianoxide, are novel compounds. The major in vivo metabolic processes associated with gentianine include N-oxide, epoxidation, dihydroxylation of double bond and hydrolysis of lactone. Gentianine together with the metabolites in plasma were quantified using gentianone as the internal standard. The mean Cmax of G0, G1, G2 and G3 are 425.76, 287.56, 188.45 and 85.05ng/mL, respectively. The mean Tmax of G0, G1, G2 and G3 are 1.16, 3.87, 6.23 and 4.28h, respectively. The mean T1/2 of G0, G1, G2 and G3 are 5.23, 12.34, 7.78 and 5.64h, respectively. A comprehensive metabolic pathway was proposed. The new metabolites may shed light on clinical efficacy of gentianine.
AB - We investigated the metabolic fate of gentianine after oral administration to Wistar rats for the first time. Liquid chromatography/ion trap mass spectrometry detected four metabolites secogentianoxide, gentiandiol, gentianepoxide and gentianoxide in rat plasma together with the original compound gentianine. The structures of the metabolites were identified by comparing the retention times, as well as MS (mass) and MS/MS (tandem mass) spectra with those of authentic compounds, which were synthesized from gentianine or isolated from the urine. Three of the metabolites, secogentianoxide, gentianepoxide and gentianoxide, are novel compounds. The major in vivo metabolic processes associated with gentianine include N-oxide, epoxidation, dihydroxylation of double bond and hydrolysis of lactone. Gentianine together with the metabolites in plasma were quantified using gentianone as the internal standard. The mean Cmax of G0, G1, G2 and G3 are 425.76, 287.56, 188.45 and 85.05ng/mL, respectively. The mean Tmax of G0, G1, G2 and G3 are 1.16, 3.87, 6.23 and 4.28h, respectively. The mean T1/2 of G0, G1, G2 and G3 are 5.23, 12.34, 7.78 and 5.64h, respectively. A comprehensive metabolic pathway was proposed. The new metabolites may shed light on clinical efficacy of gentianine.
KW - Gentianine
KW - LC-MS
KW - Metabolite
UR - http://www.scopus.com/inward/record.url?scp=84925457872&partnerID=8YFLogxK
U2 - 10.1016/j.jchromb.2015.01.007
DO - 10.1016/j.jchromb.2015.01.007
M3 - Article
C2 - 25813903
AN - SCOPUS:84925457872
SN - 1570-0232
VL - 989
SP - 98
EP - 103
JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
ER -